Trials / Completed
CompletedNCT00732420
Open-label Study of Topotecan and Pazopanib in Advanced Solid Tumors
A Phase I Open-label Study of the Safety, Tolerability, and Pharmacokinetics of Two Schedules of Oral Topotecan in Combination With Pazopanib in Subjects With Advanced Solid Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 68 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To determined what dose of topotecan can be safely given with daily pazopanib.
Detailed description
A Phase I Open-label Study of the Safety, Tolerability, and Pharmacokinetics of Two Schedules of Oral Topotecan in combination with Pazopanib in Subjects with Advanced Solid Tumors
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | topotecan | Topoisomerase I inhibition. |
| DRUG | pazopanib | Tyrosine kinase inhibitor |
Timeline
- Start date
- 2008-09-24
- Primary completion
- 2013-06-12
- Completion
- 2013-06-12
- First posted
- 2008-08-12
- Last updated
- 2017-11-13
Locations
3 sites across 2 countries: United States, Netherlands
Source: ClinicalTrials.gov record NCT00732420. Inclusion in this directory is not an endorsement.